SECO

SECO

March 01, 2013
1 min read
Save

Bausch + Lomb anticipates launch of silicone hydrogel multifocal

You've successfully added to your alerts. You will receive an email when new content is published.

Click Here to Manage Email Alerts

We were unable to process your request. Please try again later. If you continue to have this issue please contact customerservice@slackinc.com.

ATLANTA – Executives from Bausch + Lomb announced the expansion of the company’s silicone hydrogel for astigmatism as well as plans to release a multifocal version, in a meeting with Primary Care Optometry News here at SECO.

The company has expanded the PureVision2 for Astigmatism platform by adding another cylinder, Michael D. Pier, OD, director of professional relations at Bausch + Lomb, told PCON. The lens is now available from +6 D to –9 D and in four cylinders.

"Patient satisfaction is high," Pier said.

"We are now looking to launch a multifocal PureVision2 that will incorporate a new design of optics," he said.

According to Mohinder Merchea, OD, PhD, MBA, FAAO, FBCLA, B+L’s director of medical affairs – North America, Vision Care, "We are in the process of developing multifocal optics very different than what’s already available in the marketplace. We need to focus on what’s functionally important to the patient, and they really need help in the near and intermediate zones."

Merchea also shared results from a recent study indicating that the company’s contact lens solution, Biotrue, was effective against Achromobacter xylosidans, Stenotrophomonas maltophilia and Delftia acidovirans. These are the predominant gram-negative species identified as contaminating contact lens cases and causing contact lens-associated infiltrative keratitis, according to the study.

Followup statement from Bausch + Lomb:

“As part of our strong commitment to patients, Bausch + Lomb is working on new materials and lens designs, but we have not made any formal announcements about specific products.  We would only do so once they are cleared by the U.S. Food and Drug Administration, or other regulatory bodies.”